Cancer treatment | Vascular Endothelial Growth Factor Inhibitors | Vascular Endothelial Growth Factor Receptor inhibitors | bevacizumab | Avastin | sorafenib | Nexavar | sunitinib | Sutent | axitinib | AG 013736 | AZD2171
Item
ongoing treatment for malignancy by at the university of chicago with any agent with recognized, specific inhibition of vegf, vegf-receptors, or downstream signaling molecules with the specific intention of inhibiting signaling of this pathway. these agents include but are not limited to: bevacizumab (avastin™), sorafenib (nexavar™), sunitinib (sutent™), axitinib (ag-013736), and azd 2171.
boolean
C0920425 (UMLS CUI [1])
C4522891 (UMLS CUI [2])
C0148199 (UMLS CUI [3,1])
C0243077 (UMLS CUI [3,2])
C0796392 (UMLS CUI [4])
C1135130 (UMLS CUI [5])
C1516119 (UMLS CUI [6])
C1677799 (UMLS CUI [7])
C1176020 (UMLS CUI [8])
C1698963 (UMLS CUI [9])
C1700874 (UMLS CUI [10])
C1328149 (UMLS CUI [11])
C1541530 (UMLS CUI [12])
Antihypertensive therapy | Antihypertensive Agents Quantity | Blood pressure determination
Item
treatment of hypertension with at least 2 or more anti-hypertensive medications with blood pressure remaining greater than 140/90 mmhg.
boolean
C0585941 (UMLS CUI [1])
C0003364 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
C0005824 (UMLS CUI [3])
Toxicity Due to Cancer treatment | Management Stable
Item
stable management of other toxicities from the cancer treatments
boolean
C0600688 (UMLS CUI [1,1])
C0678226 (UMLS CUI [1,2])
C0920425 (UMLS CUI [1,3])
C0376636 (UMLS CUI [2,1])
C0205360 (UMLS CUI [2,2])
Cancer treatment Duration Expected
Item
expected to continue current cancer treatments for at least 4 weeks
boolean
C0920425 (UMLS CUI [1,1])
C0449238 (UMLS CUI [1,2])
C1517001 (UMLS CUI [1,3])
Age
Item
18 years and older
boolean
C0001779 (UMLS CUI [1])
Informed Consent
Item
ability to understand and the willingness to sign a written informed consent document prior to any study specific procedures.
boolean
C0021430 (UMLS CUI [1])
Erythropoietin | Erythropoietin congener
Item
concurrent use of hematopoietic supportive treatment with erythropoietin or congeners.
boolean
C0014822 (UMLS CUI [1])
C0014822 (UMLS CUI [2,1])
C0678518 (UMLS CUI [2,2])
Toxicity Uncontrolled | Toxicity Due to Cancer treatment
Item
current uncontrolled toxicities due to the cancer treatments.
boolean
C0600688 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0600688 (UMLS CUI [2,1])
C0678226 (UMLS CUI [2,2])
C0920425 (UMLS CUI [2,3])
Medical contraindication Hydralazine | Medical contraindication Minoxidil
Item
patients having known contraindications to hydralazine or minoxidil therapy.
boolean
C1301624 (UMLS CUI [1,1])
C0020223 (UMLS CUI [1,2])
C1301624 (UMLS CUI [2,1])
C0026196 (UMLS CUI [2,2])
Systolic Pressure | Diastolic blood pressure
Item
any readings of systolic blood pressure >200 mmhg or diastolic blood pressure >120 mmhg in the four (4) weeks prior to screening.
boolean
C0871470 (UMLS CUI [1])
C0428883 (UMLS CUI [2])
Minoxidil | Hydralazine
Item
use of either minoxidil or hydralazine in the six (6) months prior to screening.
boolean
C0026196 (UMLS CUI [1])
C0020223 (UMLS CUI [2])